Veracyte, Inc.
Description
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Nasal Swab Test for lung cancer diagnosis; and Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis. It is also developing Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
About
CEO
Mr. Marc A. Stapley
Employees
815
Instrument type
Common Stock
Sector
Healthcare
Industry
Diagnostics & Research
MIC code
XNMS
Address
6000 Shoreline Court, South San Francisco, CA 94080, United States
×
![Enlarged Chart]()
Oscillators
Invalid data format
Summary
Invalid data format
Moving Averages
Invalid data format
Earnings
| Date | Estimate EPS | Actual EPS | Difference | % Surprise |
|---|---|---|---|---|
| Nov 4, 2025 | — | — | — | — |
| Aug 4, 2025 | — | — | — | — |
| May 6, 2025 | — | — | — | — |
| Feb 20, 2025 | 0.10 | — | — | — |
| Nov 7, 2024 | 0.03 | 0.19 | 0.16 | 533.33% |
Earnings estimate
|
Next Quarter
(Mar 2025)
|
Next Year
(Dec 2025)
|
|||
|---|---|---|---|---|
| Number of analysts | — | 9 | — | 10 |
| Average estimate | — | 0.17 | — | 0.89 |
| Low estimate | — | -0.03 | — | 0.36 |
| High estimate | — | 0.26 | — | 1.31 |
| Last year EPS | — | 0.04 | — | 1.01 |
[stock_revenue_estimate]
Growth estimates
Current qtr
165.930%
Next qtr. (Mar 2025)
342.590%
Current year
199.420%
Next year (Dec 2025)
-11.900%
Next 5 years (per annum)
—
Past 5 years (per annum)
—
Income statement
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Fiscal date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total reported revenue | 361.05M | 296.54M | 219.51M | 117.48M | 120.37M |
| Cost of revenue | 112.90M | 101.58M | 74.40M | 41.46M | 36.52M |
| Gross profit | 248.15M | 194.95M | 145.11M | 76.03M | 83.85M |
| Operating expense | |||||
| Research & development | 57.31M | 40.60M | 29.84M | 17.20M | 14.85M |
| Selling general and admin | 184.23M | 168.52M | 181.19M | 89.12M | 82.72M |
| Other operating expenses | — | — | — | — | — |
| Operating income | -16.88M | -35.34M | -80.37M | -35.39M | -15.13M |
| Non operating interest income | |||||
| Income | 7.34M | 1.97M | 135,000 | 594,000 | 3.03M |
| Expense | 15,000 | 198,000 | 241,000 | 229,000 | 677,000 |
| Other income expense | -67.07M | -2.86M | -1.18M | 115,000 | 180,000 |
| Pretax income | -76.61M | -36.43M | -81.65M | -34.91M | -12.60M |
| Tax provision | -2.21M | 133,000 | -6.09M | — | — |
| Net income | -74.40M | -36.56M | -75.56M | -34.91M | -12.60M |
| Basic EPS | -1.02 | -0.51 | -1.11 | -0.66 | -0.27 |
| Diluted EPS | -1.02 | -0.51 | -1.11 | -0.66 | -0.27 |
| Basic average shares | 72.64M | 71.55M | 67.89M | 53.24M | 46.14M |
| Diluted average shares | 72.64M | 71.55M | 67.89M | 53.24M | 46.14M |
| EBITDA | 18.22M | -7.18M | -60.73M | -26.79M | -7.81M |
| Net income from continuing op. | -74.40M | -36.56M | -75.56M | -34.91M | -12.60M |
| Minority interests | — | — | — | — | — |
| Preferred stock dividends | — | — | — | — | — |
Balance sheet
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Fiscal date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 1.11B | 1.16B | 1.19B | 457.16M | 275.21M |
| Current assets | |||||
| Cash | — | — | — | — | — |
| Cash equivalents | — | — | — | — | — |
| Cash and cash equivalents | 216.45M | 154.25M | 173.20M | 349.36M | 159.32M |
| Other short term investments | — | 24.61M | 3.96M | — | — |
| Accounts receivable | 40.38M | 44.02M | 41.46M | 18.46M | 19.33M |
| Other receivables | — | — | — | — | — |
| Inventory | 16.13M | 14.29M | 11.23M | 4.66M | 6.81M |
| Prepaid assets | — | — | 17.22M | 3.20M | 2.24M |
| Restricted cash | — | — | — | — | — |
| Assets held for sale | — | — | — | — | — |
| Hedging assets | — | — | — | — | — |
| Other current assets | 12.66M | 11.47M | 13.26M | 3.20M | 2.24M |
| Non current assets | |||||
| Properties | 37.09M | 34.32M | 33.58M | 18.49M | 18.46M |
| Land and improvements | — | — | — | — | — |
| Machinery furniture equipment | 13.86M | 12.20M | 9.44M | 7.12M | 6.42M |
| Construction in progress | 2.47M | 587,000 | 999,000 | 761,000 | 1.02M |
| Leases | 10.31M | 9.74M | 8.61M | 6.86M | 5.93M |
| Accumulated depreciation | -32.86M | -25.98M | -21.48M | -16.40M | -14.08M |
| Goodwill | 1.49B | 1.57B | 1.62B | 65.37M | 70.47M |
| Investment properties | — | — | — | — | — |
| Financial assets | — | — | — | — | — |
| Intangible assets | 88.59M | 174.87M | 202.73M | 59.92M | 65.02M |
| Investments and advances | — | — | — | — | — |
| Other non current assets | 6.85M | 6.17M | 2.95M | 2.00M | 2.04M |
| Total liabilities | 70.80M | 81.22M | 91.31M | 35.93M | 35.76M |
| Current liabilities | |||||
| Accounts payable | 12.94M | 11.91M | 12.36M | 3.12M | 2.33M |
| Accrued expenses | 12.00M | 7.14M | 8.68M | 2.50M | 3.63M |
| Short term debt | 5.11M | 4.07M | 4.76M | 1.59M | 1.41M |
| Deferred revenue | 2.01M | 2.61M | 4.65M | 371,000 | — |
| Tax payable | — | — | — | — | — |
| Pensions | 26.43M | 30.64M | 30.79M | 9.20M | 10.10M |
| Other current liabilities | 2.76M | 6.25M | 2.91M | — | — |
| Non current liabilities | |||||
| Long term debt | 7.53M | 10.65M | 14.10M | 10.73M | 12.20M |
| Provision for risks and charges | — | — | — | — | — |
| Deferred liabilities | 734,000 | 4.53M | 5.59M | — | — |
| Derivative product liabilities | — | — | — | — | — |
| Other non current liabilities | 1.30M | 3.43M | 7.13M | 7.59M | 6.09M |
| Shareholders equity | |||||
| Common stock | 73,000 | 72,000 | 71,000 | 58,000 | 50,000 |
| Retained earnings | -468.12M | -393.72M | -357.16M | -281.59M | -246.69M |
| Other shareholders equity | -24.02M | -31.35M | -15.08M | — | — |
| Total shareholders equity | 1.04B | 1.08B | 1.10B | 421.23M | 239.46M |
| Additional paid in capital | 1.54B | 1.50B | 1.47B | 702.77M | 486.09M |
| Treasury stock | — | — | — | — | — |
| Minority interest | — | — | — | — | — |
Cash flow statement
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||||||||
| Net Income | -74.40M | -36.56M | -75.56M | -34.91M | -12.60M | -23.00M | -31.00M | -31.36M | -33.70M | -29.37M | -25.58M | -18.65M | -14.45M |
| Depreciation | 27.19M | 25.93M | 19.59M | 7.94M | 4.12M | 3.92M | 3.84M | 3.51M | 2.25M | 1.18M | 999,000 | 706,000 | 611,000 |
| Deferred Taxes | -3.84M | 133,000 | -6.26M | — | — | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | 33.14M | 26.73M | 22.52M | 13.00M | 9.81M | 5.96M | 6.62M | 6.38M | 5.60M | 3.55M | 1.25M | 934,000 | 659,000 |
| Other Non-Cash Items | -1.23M | 3.64M | 2.66M | 2.69M | 1.35M | 251,000 | 2.06M | -184,000 | -1.77M | -2.09M | -332,000 | -2.66M | -719,000 |
| Accounts Receivable | 3.89M | -4.50M | -8.57M | 955,000 | -6.16M | -452,000 | -3.96M | -5.32M | -558,000 | -1.96M | -683,000 | -565,000 | -463,000 |
| Accounts Payable | -134,000 | 152,000 | 5.16M | 711,000 | -141,000 | -1.57M | 1.73M | -1.44M | -3.55M | 1.87M | 3.35M | 1.35M | 116,000 |
| Other Assets & Liabilities | -6.78M | -9.51M | -3.47M | -272,000 | -5.13M | 402,000 | -2.23M | 342,000 | -155,000 | -1.22M | -1.47M | 9.11M | -145,000 |
| Operating Cash Flow | -22.17M | 6.02M | -43.94M | -9.89M | -8.76M | -14.49M | -22.95M | -28.07M | -31.88M | -28.05M | -22.47M | -9.78M | -14.39M |
| Investing Activities | |||||||||||||
| Capital Expenditures | -9.96M | -8.55M | -5.38M | -2.84M | -2.73M | -1.87M | -1.32M | -4.21M | -6.17M | -2.02M | -1.33M | -1.46M | -276,000 |
| Net Intangibles | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Net Acquisitions | — | — | -736.83M | — | -40.00M | — | — | — | — | -6.92M | — | — | — |
| Purchase of Investments | -19.70M | -33.52M | — | -1.00M | — | — | — | — | — | — | — | — | — |
| Sale of Investments | 44.77M | 12.68M | 3.00M | — | — | — | — | — | — | — | — | — | — |
| Investing Cash Flow | 15.11M | -29.39M | -739.21M | -3.84M | -42.73M | -1.87M | -1.20M | -4.21M | -6.70M | -9.01M | -1.28M | -1.46M | -331,000 |
| Financing Activities | |||||||||||||
| Long-Term Debt Issuance | — | — | — | — | — | — | 24.88M | 24.45M | — | — | 4.88M | — | — |
| Long-Term Debt Payments | — | -1.28M | — | -100,000 | -25.21M | -292,000 | -27.20M | -5.29M | — | -110,000 | — | — | — |
| Other Financing Charges | -6.74M | -3.17M | -9.03M | -3.85M | -977,000 | 373,000 | — | — | -247,000 | -129,000 | -7.02M | — | — |
| Financing Cash Flow | -6.74M | -4.45M | 584.79M | 189.89M | 111.66M | 55.12M | -2.12M | 51.11M | 37.01M | -368,000 | 70.09M | 14.99M | 18.62M |
| Other Cash Details | |||||||||||||
| End Cash Position | 217.33M | 155.00M | 173.95M | 349.97M | 159.92M | 78.60M | 34.49M | 59.94M | 39.08M | 35.01M | 71.22M | 14.00M | 7.57M |
| Income Tax Paid | 1.70M | 570,000 | 112,000 | 112,000 | 35,000 | 79,000 | 21,000 | 7,000 | 22,000 | — | — | — | — |
| Interest Paid | — | 9,000 | 9,000 | 13,000 | 332,000 | 1.55M | 2.72M | 2.15M | 278,000 | 307,000 | 132,000 | — | — |
| Free Cash Flow | 34.26M | -1.01M | -37.00M | -12.55M | -5.99M | -15.40M | -25.67M | -32.19M | -33.13M | -29.66M | -20.49M | -8.63M | -13.80M |
Top Institutional Holders
| Holder | Date Reported | Shares | Value | % Held |
|---|---|---|---|---|
| ARK ETF Tr-ARK Innovation ETF | Nov 30, 2024 | 2,849,544 | 128.80M | 3.68% |
| Vanguard Explorer Fund, Inc. | Oct 31, 2024 | 2,800,054 | 126.56M | 3.61% |
| Vanguard Total Stock Market Index Fund | Sep 30, 2024 | 2,464,621 | 111.40M | 3.18% |
| iShares Russell 2000 ETF | Nov 30, 2024 | 2,156,759 | 97.49M | 2.78% |
| Vanguard Small-Cap Index Fund | Sep 30, 2024 | 1,921,042 | 86.83M | 2.48% |
| ARK ETF Tr-ARK Genomic Revolution ETF | Nov 30, 2024 | 1,491,393 | 67.41M | 1.92% |
| Artisan Small Cap Fund | Sep 30, 2024 | 1,225,936 | 55.41M | 1.58% |
| Vanguard Extended Market Index Fund | Sep 30, 2024 | 1,155,988 | 52.25M | 1.49% |
| Vanguard Small-Cap Growth Index Fund | Sep 30, 2024 | 1,059,073 | 47.87M | 1.37% |
| SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF | Nov 30, 2024 | 987,181 | 44.62M | 1.27% |
Article
New Study Shows Veracyte's Decipher Bladder Test Predicts Disease Upstaging in Patients with Bladder Cancer
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT--New Study Shows Veracyte's Decipher Bladder Test Predicts Disease Upstaging in Patients with Bladder Cancer.
Feb 5, 2025
Article
Veracyte to Release Fourth Quarter and Full-Year 2024 Financial Results on February 24, 2025
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that it will release financial results for the fourth quarter and full-year 2024 after the close of market on Monday, February 24, 2025. Company management will host a conference call and webcast to discuss financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day. The conference call will be webcast live from the company's we.
Feb 4, 2025
Article
Veracyte Gains 44% in a Year: What's Driving the Stock?
VCYT is gaining shares due to the strength of its Afirma and Decipher tests.
Jan 6, 2025
